News Brief
CDSCO Approves Novo Nordisk’s Ozempic For Type 2 Diabetes And Obesity in India
Ozempic is a semaglutide-based injection
In a major development, the Central Drugs Standard Control Organisation (CDSCO) has approved Ozempic, a semaglutide-based once-weekly injection from Novo Nordisk, for use in India.
The regulatory nod on 30 September 2025 allows the medication to address the rising prevalence of Type 2 diabetes and obesity in the country.
Ozempic, intended for adults whose diabetes is not adequately controlled through diet and exercise alone, has garnered international recognition for its dual benefits, improving glycaemic control and aiding weight loss.
It also helps reduce the risk of major cardiovascular events, including heart attacks and strokes, in patients with established heart disease.
Vikrant Shrotiya, Novo Nordisk India head, called the launch a “welcome change” in tackling India’s diabetes epidemic.
The drug will be available strictly on prescription, with experts cautioning against potential misuse, especially for off-label weight management.
The Indian market for anti-obesity medications is currently valued at Rs 752 crore, with semaglutide occupying Rs 426 crore.
While pricing details remain undisclosed, similar therapies cost Rs 14,000–26,000 per month, raising affordability concerns in a price-sensitive market.
Clinical studies highlight significant weight reduction and cardiovascular benefits, but side effects such as nausea, vomiting, pancreatitis, and thyroid tumour warnings necessitate careful medical supervision.
With over 135 million Indians affected by obesity, Ozempic’s approval aligns with the country’s growing need for advanced therapeutic options.
Its entry follows the launch of Wegovy, another semaglutide-based drug, in June 2025, intensifying competition in the GLP-1 receptor agonist segment.
Stakeholders expect the drug to become available soon, with vigilance urged against counterfeit products amid high demand.
